ValuEngine Lowers ChemoCentryx, Inc. (CCXI) to Sell
ValuEngine cut shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a sell rating in a research note released on Saturday morning.
CCXI has been the subject of several other research reports. Cowen and Company restated a hold rating on shares of ChemoCentryx in a report on Tuesday, August 8th. Zacks Investment Research upgraded ChemoCentryx from a hold rating to a buy rating and set a $12.00 price objective for the company in a report on Monday, July 17th. Finally, BidaskClub cut ChemoCentryx from a buy rating to a hold rating in a report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $9.00.
Shares of ChemoCentryx (CCXI) opened at 6.75 on Friday. ChemoCentryx has a 12 month low of $5.52 and a 12 month high of $10.80. The firm’s market cap is $328.77 million. The firm has a 50 day moving average price of $7.50 and a 200-day moving average price of $7.84.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The firm had revenue of $8.94 million during the quarter. On average, analysts predict that ChemoCentryx will post ($0.90) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/valuengine-lowers-chemocentryx-inc-ccxi-to-sell/1650467.html.
A number of large investors have recently modified their holdings of CCXI. Russell Investments Group Ltd. lifted its stake in ChemoCentryx by 51.5% in the 1st quarter. Russell Investments Group Ltd. now owns 94,165 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 31,997 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in ChemoCentryx by 37.5% in the 1st quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after purchasing an additional 35,049 shares during the last quarter. Thrivent Financial For Lutherans acquired a new stake in ChemoCentryx in the 1st quarter valued at about $852,000. Vanguard Group Inc. lifted its stake in ChemoCentryx by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after purchasing an additional 47,475 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in ChemoCentryx by 4.6% in the 1st quarter. Geode Capital Management LLC now owns 196,708 shares of the biopharmaceutical company’s stock valued at $1,432,000 after purchasing an additional 8,697 shares during the last quarter. Institutional investors and hedge funds own 49.31% of the company’s stock.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.